A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

NCT05975268 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

747

Enrollment

OTHER

Sponsor class

Conditions

Moderate to Severe Chronic Plaque Psoriasis

Interventions

BIOLOGICAL: JS005 (recombinant humanized monoclonal antibody against IL-17A)

Sponsor

Shanghai Junshi Bioscience Co., Ltd.